000884702 001__ 884702
000884702 005__ 20220930130252.0
000884702 0247_ $$2doi$$a10.3390/ph13090256
000884702 0247_ $$2Handle$$a2128/25697
000884702 0247_ $$2altmetric$$aaltmetric:90834376
000884702 0247_ $$2pmid$$apmid:32961780
000884702 0247_ $$2WOS$$aWOS:000580249000001
000884702 037__ $$aFZJ-2020-03203
000884702 082__ $$a610
000884702 1001_ $$0P:(DE-HGF)0$$aWiedenhoeft, Tabea$$b0
000884702 245__ $$aThe Basement Membrane in a 3D Breast Acini Model Modulates Delivery and Anti-Proliferative Effects of Liposomal Anthracyclines 
000884702 260__ $$aBasel$$bMDPI$$c2020
000884702 3367_ $$2DRIVER$$aarticle
000884702 3367_ $$2DataCite$$aOutput Types/Journal article
000884702 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600696820_28605
000884702 3367_ $$2BibTeX$$aARTICLE
000884702 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000884702 3367_ $$00$$2EndNote$$aJournal Article
000884702 520__ $$aBreast cancer progression is marked by cancer cell invasion and infiltration, which can be closely linked to sites of tumor-connected basement membrane thinning, lesion, or infiltration. Bad treatment prognosis frequently accompanies lack of markers for targeted therapy, which brings traditional chemotherapy into play, despite its adverse effects like therapy-related toxicities. In the present work, we compared different liposomal formulations for the delivery of two anthracyclines, doxorubicin and aclacinomycin A, to a 2D cell culture and a 3D breast acini model. One formulation was the classical phospholipid liposome with a polyethylene glycol (PEG) layer serving as a stealth coating. The other formulation was fusogenic liposomes, a biocompatible, cationic, three-component system of liposomes able to fuse with the plasma membrane of target cells. For the lysosome entrapment-sensitive doxorubicin, membrane fusion enabled an increased anti-proliferative effect in 2D cell culture by circumventing the endocytic route. In the 3D breast acini model, this process was found to be limited to cells beneath a thinned or compromised basement membrane. In acini with compromised basement membrane, the encapsulation of doxorubicin in fusogenic liposomes increased the anti-proliferative effect of the drug in comparison to a formulation in PEGylated liposomes, while this effect was negligible in the presence of intact basement membranes
000884702 536__ $$0G:(DE-HGF)POF3-552$$a552 - Engineering Cell Function (POF3-552)$$cPOF3-552$$fPOF III$$x0
000884702 7001_ $$0P:(DE-Juel1)151181$$aBraun, Tobias$$b1
000884702 7001_ $$0P:(DE-Juel1)144199$$aSpringer, Ronald$$b2$$ufzj
000884702 7001_ $$0P:(DE-Juel1)174293$$aTeske, Michael$$b3
000884702 7001_ $$0P:(DE-Juel1)145698$$aNoetzel, Erik$$b4$$ufzj
000884702 7001_ $$0P:(DE-Juel1)128833$$aMerkel, Rudolf$$b5$$ufzj
000884702 7001_ $$0P:(DE-Juel1)128805$$aCsiszar, Agnes$$b6$$eCorresponding author
000884702 773__ $$0PERI:(DE-600)2193542-7$$a10.3390/ph13090256$$n9$$p256$$tPharmaceuticals$$v13$$x1424-8247$$y2020
000884702 8564_ $$uhttps://juser.fz-juelich.de/record/884702/files/Invoice_MDPI_pharmaceuticals-936618_1102.57EUR.pdf
000884702 8564_ $$uhttps://juser.fz-juelich.de/record/884702/files/Invoice_MDPI_pharmaceuticals-936618_1102.57EUR.pdf?subformat=pdfa$$xpdfa
000884702 8564_ $$uhttps://juser.fz-juelich.de/record/884702/files/pharmaceuticals-13-00256.pdf$$yOpenAccess
000884702 8564_ $$uhttps://juser.fz-juelich.de/record/884702/files/pharmaceuticals-13-00256.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000884702 8767_ $$8936618$$92020-09-16$$d2020-09-23$$eAPC$$jZahlung erfolgt$$zBelegnr.: 1200157464
000884702 909CO $$ooai:juser.fz-juelich.de:884702$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000884702 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144199$$aForschungszentrum Jülich$$b2$$kFZJ
000884702 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145698$$aForschungszentrum Jülich$$b4$$kFZJ
000884702 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)128833$$aForschungszentrum Jülich$$b5$$kFZJ
000884702 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)128805$$aForschungszentrum Jülich$$b6$$kFZJ
000884702 9131_ $$0G:(DE-HGF)POF3-552$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vEngineering Cell Function$$x0
000884702 9141_ $$y2020
000884702 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-02
000884702 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000884702 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000884702 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-02
000884702 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-02
000884702 920__ $$lyes
000884702 9201_ $$0I:(DE-Juel1)IBI-2-20200312$$kIBI-2$$lMechanobiologie$$x0
000884702 980__ $$ajournal
000884702 980__ $$aVDB
000884702 980__ $$aUNRESTRICTED
000884702 980__ $$aI:(DE-Juel1)IBI-2-20200312
000884702 980__ $$aAPC
000884702 9801_ $$aAPC
000884702 9801_ $$aFullTexts